S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00939328
Recruitment Status : Withdrawn (question was no longer committee priority)
First Posted : July 15, 2009
Last Update Posted : March 6, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group

July 14, 2009
July 15, 2009
March 6, 2015
September 2009
September 2010   (Final data collection date for primary outcome measure)
  • Response rate (CR, CRi, or PR)
  • Safety and tolerability
Same as current
Complete list of historical versions of study NCT00939328 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
S0902, Phase II Study of Bendamustine Plus Rituximab for the Treatment of Refractory B-Cell Chronic Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Giving bendamustine together with rituximab may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects of giving bendamustine together with rituximab and to see how well it works in treating patients with B-cell chronic lymphocytic leukemia that has not responded to previous treatment.


  • To test whether the response rate (CR, CRi, or PR) in patients with purine analog-refractory, B-cell chronic lymphocytic leukemia (CLL) after treatment with the combination of bendamustine hydrochloride and rituximab is sufficiently high to warrant further investigation.
  • To evaluate the safety and tolerability of bendamustine hydrochloride and rituximab in patients with B-cell CLL who are refractory to treatment with a purine-nucleoside analog-containing regimen.
  • To investigate, in a preliminary manner, the prognostic effects of pre-treatment cytogenetic abnormalities identified by conventional cytogenetics and by FISH analyses on response to treatment in this patient population.

OUTLINE: This is a multicenter study.

Patients receive rituximab IV on day 1 and bendamustine IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. In course 1 only, patients also receive rituximab IV on day 2.

After completion of study treatment, patients are followed up periodically for 2 years.

Phase 2
Masking: None (Open Label)
Primary Purpose: Treatment
  • Biological: rituximab
  • Drug: bendamustine hydrochloride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2010
September 2010   (Final data collection date for primary outcome measure)


  • Histologically and immunophenotypically confirmed diagnosis of B-cell chronic lymphocytic leukemia (CLL)

    • Progressive or symptomatic disease
    • Purine analog-refractory disease
  • Must meet 1 of the following criteria:

    • Intermediate- or high-risk modified-Rai stage
    • Low-risk modified-Rai stage and progressive lymphocytosis, defined as > 50% increase of absolute peripheral lymphocyte count over the lowest count during the past 2 months
  • Received 1 or more prior therapies for CLL
  • Must be registered on SWOG-9007, "Cytogenetic Studies in Leukemia Patients"


  • Zubrod performance status 0-3
  • ANC > 1,000/mm³
  • Platelet count > 50,000/mm³
  • Serum creatinine ≤ 2 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No systemic fungal, bacterial, viral, or other infection that is not controlled (i.e., exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
  • No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for 5 years
  • HIV positivity allowed provided the following criteria are met:

    • CD4 cells > 350/mm³
    • No concurrent antiretroviral therapy


  • See Disease Characteristics
  • More than 28 days since prior chemotherapy, any other investigational agents, or major surgery
  • More than 120 days since prior allogeneic or autologous hematopoietic stem cell transplantation

    • If prior allogeneic bone marrow transplantation, must meet the following criteria:

      • Performed > 120 days ago
      • No acute graft-vs-host disease (GVHD) ≥ grade 2
      • Receiving no immunosuppressive therapy for chronic GVHD
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No concurrent CYP1A2 inhibitors
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
S0902 ( Other Identifier: SWOG )
U10CA032102 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Southwest Oncology Group
Southwest Oncology Group
National Cancer Institute (NCI)
Study Chair: Matt E. Kalaycio, MD The Cleveland Clinic
Southwest Oncology Group
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP